For several years now, popPK has taken an essential place in the drug development program and can be applied at all phases of drug development, adapting each time to clinical constraints. The agencies encourage more and more the use of popPK modelling to inform drug development and use. Indeed, The US Food and Drug Administration (FDA) released new draft guidance on Population Pharmacokinetics (popPK) in July of 2019. To present and explain this practice we interviewed Sarah Lezzar, Pharmacometrician and Biostatistician at PhinC Development.
Read the full article by clicking below!